Skip Navigation


Rheumatology Advance Access originally published online on April 27, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/6/790    most recent
keh198v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Williamson, L.
Right arrow Articles by Wordsworth, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williamson, L.
Right arrow Articles by Wordsworth, B. P.
Related Collections
Right arrow Spondylarthropathies
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2004; 43: 790-794
Rheumatology Vol. 43 No. 6 © British Society for Rheumatology 2004; all rights reserved


Clinical

Extended report: nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked

L. Williamson, N. Dalbeth, J. L. Dockerty, B. C. Gee1, R. Weatherall2 and B. P. Wordsworth

Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford, 1 Department of Dermatology, Churchill Hospital, Oxford and 2 ICRF/NHS Centre for Statistics in Medicine, Institute of Health Sciences, Oxford, UK.

Correspondence to: L. Williamson, The Great Western Hospital, Swindon SN1 4JU, UK. E-mail: lyn.williamson{at}smnhst.swest.nhs.uk

Objectives. To examine the relationship between the severity of nail disease and characteristics of psoriatic arthritis (PsA). We also wished to assess the clinical management of nail disease in patients with PsA.

Methods. We studied 69 patients with PsA at two visits. On the first visit, a rheumatology assessment of joint, skin and nail disease was made. On the second visit, a detailed dermatology assessment of skin and nails was made. Nail disease was analysed using a 20-nail psoriasis nail severity score (PNSS).

Results..There were 57 (83%) patients with clinical evidence of psoriatic nail disease. Although 66 (96%) patients had been treated for skin disease, only one (1%) had received any treatment for nail disease. Severe nail disease measured by the PNSS correlated with severe skin psoriasis as indicated by the percentage of body surface area affected by psoriasis (r = 0.34, P = 0.004) and physician global assessment of psoriasis (r = 0.45, P<0.001). Patients with distal interphalangeal (DIP) joint disease had higher PNSS scores (P = 0.03). The PNSS was also associated with unremitting and progressive arthritis (P<0.001), and correlated with Stanford health assessment questionnaire (HAQ) (r = 0.34, P = 0.004), depression (r = 0.39, P<0.001) and anxiety (r = 0.34, P = 0.004) scores. Compared with dermatology assessment, the rheumatology examination of nail disease had a positive predictive value of 84% and negative predictive value of 83%.

Conclusions. In patients with PsA, the severity of nail disease correlates with indicators of severity of both skin and joint disease. Although rheumatologists can adequately screen for nail disease, the management of this aspect of PsA is often overlooked.

KEY WORDS: Psoriatic arthritis, Nail disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Rheumatology (Oxford)Home page
A. L. Tan, M. Benjamin, H. Toumi, A. J. Grainger, S. F. Tanner, P. Emery, and D. McGonagle
The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study
Rheumatology, February 1, 2007; 46(2): 253 - 256.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
S. Kyle, D. Chandler, C. E. M. Griffiths, P. Helliwell, J. Lewis, I. McInnes, S. Oliver, D. Symmons, N. McHugh, and on behalf of the British Society for Rheumatology
Guideline for anti-TNF-{alpha} therapy in psoriatic arthritis
Rheumatology, March 1, 2005; 44(3): 390 - 397.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.